GALWAY, Ireland, 15 April 2026 - Boston Scientific Corporation (NYSE: BSX) – a global leader in medical device technology – today announced a €75 million investment in its Galway site, including the expansion of its research and development (R&D) capabilities, further strengthening its role as a global centre for cardiovascular innovation.
The development, which is supported by funding from the Irish government through IDA Ireland, includes purpose-built laboratories to enhance the ability of teams in Galway to design, develop and test next-generation medical technologies across a range of cardiovascular therapies.
The expanded capability will support priority programmes across structural heart, cardiovascular and endoscopy, as well as emerging areas such as heart failure and renal denervation technologies, underpinned by a strong regional talent base and STEM ecosystem.
Regarding the announcement, Minister for Education and Youth, Hildegarde Naughton said: “The decision by Boston Scientific to invest again in Galway shows real confidence in the talent and infrastructure available here. The importance of R&D and innovation to Ireland’s economy cannot be overstated. It is achieved through a strong partnership between industry, Government and IDA Ireland and has acknowledged that Galway is now an internationally recognised MedTech hub. This is due in no small part to the presence of Boston Scientific, one of the largest life sciences employers in the country, and I want to very much thank them for their continued investment.”
As a global leader in medical technology innovation, Boston Scientific continues to invest in capabilities that advance patient care, with Galway playing a key role in delivering that innovation.
“We are seeing strong momentum across our cardiovascular business, and this investment reflects the important role the Galway site plays in that progress,” said Lance Bates, executive vice president and president, Interventional Cardiology and Vascular Therapies, Boston Scientific. “The local team is delivering complex, highly collaborative work that is advancing meaningful innovation for patients. The strength of the site, the talent in Ireland and the support of the Irish Government and IDA Ireland give us confidence to continue investing in our future growth.”
Boston Scientific has a long-established presence in Ireland spanning over 30 years, with over 7,000 employees across sites in Galway, Cork and Clonmel producing over 30 million devices each year for patients worldwide.
Medical devices exported from the Galway facility every year include drug-coated devices, vascular balloons and heart and oesophageal stents. These products help treat patients with conditions including heart disease, vascular disease, oesophageal cancer and those at risk of stroke.
Rachel Shelly, Global Head of Life Sciences at IDA Ireland, stated: “Boston Scientific’s €75 million R&D investment in Galway reinforces Ireland’s leadership in medical technology innovation. For more than 30 years, Boston Scientific has invested in advanced manufacturing and innovative technologies in Ireland, benefiting patients, communities and ecosystems locally and globally. IDA Ireland looks forward to continued collaboration with Boston Scientific to advance MedTech excellence.”
 |
 |
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.eu and follow us on LinkedIn.
CONTACTS:
Emily Brand
Corporate Communications